Genomtec (GMT) Q2 2025 earnings summary

Executive summary

• Focus on R&D in molecular diagnostics, with Genomtec ID and OncoSNAAT as flagship projects.

• No significant product sales; revenues mainly from grants and one-off orders.

• Strategic goal is commercialization via partnerships, licensing, or technology sale.

• Two new subsidiaries established for project asset allocation.

Financial highlights

• Revenue from sales: PLN 11,000 (up from PLN 1,000 year-over-year).

• Net loss: PLN -6,555,000 (vs. PLN -6,040,000 year-over-year).

• R&D expenses: PLN 4,168,000 (vs. PLN 1,583,000 year-over-year).

• Cash and equivalents: PLN 9,876,000 (up from PLN 6,697,000 at year-end 2024).

• Equity: PLN 12,901,000 (up from PLN 7,600,000 at year-end 2024).

Outlook and guidance

• No material product sales expected in the near term; commercialization depends on successful partnerships.

• Further funding required for continued R&D and commercialization.

• Key revenue drivers will be grants, investor contributions, and potential licensing deals.